Andra AP fonden Acquires New Shares in Regeneron Pharmaceuticals, Inc. $REGN

Andra AP fonden acquired a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 4,232 shares of the biopharmaceutical company’s stock, valued at approximately $3,270,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. WPG Advisers LLC increased its holdings in shares of Regeneron Pharmaceuticals by 312.5% in the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 25 shares in the last quarter. SHP Wealth Management acquired a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth about $26,000. Titan Wealth CI Ltd bought a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at about $29,000. Kemnay Advisory Services Inc. bought a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at about $31,000. Finally, Entrust Financial LLC acquired a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at approximately $32,000. 83.31% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on REGN. Cantor Fitzgerald lowered their target price on Regeneron Pharmaceuticals from $785.00 to $750.00 and set an “overweight” rating for the company in a research note on Monday, July 6th. Citigroup lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price target for the company from $900.00 to $700.00 in a research note on Monday, May 18th. Truist Financial reduced their price target on shares of Regeneron Pharmaceuticals from $778.00 to $769.00 and set a “buy” rating for the company in a report on Tuesday, July 7th. Sanford C. Bernstein lowered their price objective on shares of Regeneron Pharmaceuticals from $925.00 to $921.00 and set an “outperform” rating for the company in a research report on Wednesday, April 8th. Finally, Royal Bank Of Canada dropped their price objective on shares of Regeneron Pharmaceuticals from $707.00 to $696.00 and set a “sector perform” rating on the stock in a report on Tuesday, July 7th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $787.88.

More Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Guggenheim raised its price target on Regeneron to $1,000 from $995 and reiterated a buy rating, signaling continued confidence in the company’s longer-term upside. Benzinga
• Neutral Sentiment: Regeneron also provided an update that its mid-stage POTS study for REGN7544 has wrapped up, but the article does not include enough detail to gauge the readout’s financial or clinical impact yet. TipRanks
• Negative Sentiment: Several firms, including Bronstein, Gewirtz & Grossman, Bernstein Liebhard, Bleichmar Fonti & Auld, Pomerantz, the Schall Law Firm, and others, announced or promoted a class action lawsuit against Regeneron over alleged securities-law violations tied to trial disclosures and the subsequent stock decline, keeping legal risk in focus for investors. PR Newswire

Insiders Place Their Bets

In related news, Director Arthur F. Ryan sold 200 shares of the business’s stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total transaction of $130,030.00. Following the transaction, the director directly owned 17,303 shares in the company, valued at approximately $11,249,545.45. The trade was a 1.14% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ REGN opened at $651.18 on Thursday. The stock has a 50 day moving average price of $637.84 and a 200 day moving average price of $715.73. Regeneron Pharmaceuticals, Inc. has a 52 week low of $541.00 and a 52 week high of $821.11. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.96 and a current ratio of 3.57. The stock has a market capitalization of $68.84 billion, a PE ratio of 15.87, a price-to-earnings-growth ratio of 1.50 and a beta of 0.24.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, topping the consensus estimate of $8.91 by $0.56. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The firm had revenue of $3.61 billion for the quarter, compared to analyst estimates of $3.48 billion. During the same quarter in the previous year, the firm earned $8.22 EPS. The business’s quarterly revenue was up 19.0% on a year-over-year basis. Analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.12 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, June 4th. Investors of record on Wednesday, May 20th were paid a $0.94 dividend. The ex-dividend date of this dividend was Wednesday, May 20th. This represents a $3.76 annualized dividend and a dividend yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 9.16%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.